Hydrocortisone and Fludrocortisone for the Treatment of Septic Shock

Recruiting now · Phase 4

Conditions studied: Septic Shock

In brief

The purpose of this study is to evaluate the efficacy and safety of the combination therapy of hydrocortisone and fludrocortisone among adult patients with septic shock.

Key facts

Study ID

NCT07383103

Run by

Northern Jiangsu People's Hospital

People needed

336

Starts

2026-03-02

Expected to finish

2028-12-31

Last updated by the study team

2026-03-04

Who can join

Age: 18 and older, up to 90. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• (1)18≤Age≤90; (2)Diagnosis of septic shock within 12 h.

You may not qualify if…

• Patients meeting any of the following conditions will be excluded:
• Systemic corticosteroid therapy within the last 3 months before septic shock;
• High-dose steroid therapy;
• Immunosuppression;
• Pregnant;
• Known allergy to hydrocortisone or fludrocortisone;
• Presence of gastrointestinal bleeding, perforation, or other conditions requiring fasting;
• Anticipated death from a preexisting disease within 90 days after randomization (as determined by the enrolling physician);
• Refusal of the attending staff or patient family;
• Current participation in another clinical trial.

Where it is running

• Northern Jiangsu People's Hospital — Yangzhou, Jiangsu, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.